Gut

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

Background Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in ...
Gut

Metastatic pancreatic cancer: from human disease to preclinical modelling

Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers, portending poor patient outcomes ...
Gut

A durably colonising engineered native symbiont enables sustained intestinal delivery for metabolic dysfunction and colitis

Background Engineered bacterial therapeutics represent a promising strategy for sustained intestinal delivery of therapeutic ...
Gut

Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC

Background Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma ...
Gut

Divergent microbial preludes to necrotising enterocolitis defined by gut phages and bacterial resistomes

Background Translating microbiome correlations into robust predictive features for complex gut disorders remains elusive, partly due to oversimplified models of pathogenesis and neglect of the virome, ...
gut.bmj

Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis: a double-blind, parallel-group, placebo-controlled ...

Background Pain in chronic pancreatitis (CP) is multifactorial. Efficacy of pancreatic enzyme replacement therapy (PERT) for pain remains uncertain. Objective To assess the effect of ...
gut.bmj

Multi-kingdom signatures of the gut microbiome in Lynch syndrome: a prospective model for colorectal cancer evolution

Recent work in Gut has highlighted multi-kingdom interactions between gut bacteria and bacteriophage (‘phage’) as contributors to Crohn’s disease.1 Whether similar alterations characterise colorectal ...
gut.bmj

Rare cause of epigastric distension and vomiting

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj

Deferring first surveillance to 3 years after colorectal ESD is not supported by these data

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj

Macropinocytosis of neutrophil extracellular trap by gastric cancer cells promotes immune escape and peritoneal metastasis

Background Patients with gastric cancer (GC) and peritoneal metastasis (PM) have poor prognoses due to drug resistance and metastatic relapse. The mechanism underlying PM recurrence remains unclear.
gut.bmj

Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study

Background New-onset diabetes (NOD) increases the risk of pancreatic cancer. Previous studies have mainly focused on the presence or absence of diabetes, with limited attention to NOD severity at ...
gut.bmj

Letter in reply: should SNRIs be considered the most effective neuromodulators for IBS?

We would like to thank von Muhlenbrock et al for their letter1 and for their interest in our recent network meta-analysis.2 Some gut-brain neuromodulators, particularly tricyclic antidepressants (TCAs ...